Cue Biopharma Selects Lead Candidate Cue-101 Targeting Human Papillomavirus, Associated Cancers.
M2 PHARMA-March 23, 2017-Cue Biopharma Selects Lead Candidate Cue-101 Targeting Human Papillomavirus, Associated Cancers
(C)2017 M2 COMMUNICATIONS
- US-based immunotherapy company Cue Biopharma, Inc's lead candidate, Cue-101, which targets human papillomavirus -associated cancers, has been selected, the company said.
The company expects Cue-101 to enter the clinic in the first half of 2018.
Cue-101 couples Interleukin-2 with a T cell antigen (HPV-E7 oncoprotein) in a single biologic to target and activate T cells specific to HPV-associated cancers.
Focusing the signaling effects of IL-2 on disease relevant anti-tumor T cells holds the promise of maximising efficacy while avoiding the collateral toxicity associated with systemic administration of this cytokine.
Further, Cue's selective T cell activation approach enables synergistic combinations with existing therapies, such as checkpoint inhibitors, with lower compounded toxicities.
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease.
Cue biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies.
Through this platform approach, Cue has developed a promising pipeline with its lead candidate currently approaching the clinic.
Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific/clinical advisory board with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 23, 2017|
|Previous Article:||Global Erythropoietin Drugs Market to Reach USD 10.39bn by 2021, Technavio Forecasts.|
|Next Article:||Alexion Submits Application in Japan for Soliris for Patients with Refractory Generalized Myasthenia Gravis.|